tetravalent RNA-lipoplex cancer vaccine BNT111

{
  "id": "MLC-T-ONC-017093",
  "term": "tetravalent RNA-lipoplex cancer vaccine BNT111",
  "field": "Oncology and biomedicine",
  "definition": "A RNA-lipoplex (RNA-LIP)-based cancer vaccine containing four naked ribonucleic acid (RNA)-drug products (DPs) RBL001.1, RBL002.2, RBL003.1, and RBL004.1 encoding the four melanoma-associated antigens (MAAs), the cancer-testis antigen NY-ESO-1, the human melanoma-associated antigen A3 (MAGE-A3), tyrosinase, and putative tyrosine-protein phosphatase (TPTE), encapsulated in liposomes, with potential antineoplastic activity. Upon intravenous administration of the tetravalent RNA-lipoplex cancer vaccine BNT111, the liposomes protect the RNA from degradation in the bloodstream, travel to the spleen and are taken up by antigen-presenting cells (APCs). The RNA is translocated to the cytoplasm and translated into the four tumor-associated proteins. The expressed proteins are processed and the human leukocyte antigen (HLA)-peptide complexes are presented to the immune system. This results in the production of various pro-inflammatory cytokines and induces antigen-specific CD8+ and CD4+ T-cell responses against the four selected MAAs NY-ESO-1, MAGE-A3, tyrosinase, and TPTE.",
  "synonyms": [
    "cancer vaccine BNT111",
    "lipo-MERIT vaccine",
    "RNA-LPX BNT111",
    "RNA(LIP) BNT111",
    "RNA-lipoplex vaccine BNT111"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tetravalent-rna-lipoplex-cancer-vaccine-bnt111/"
}